ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0710

The Association of IgA Vasculitis and Malignancy in Adults: A Systematic Review

Hila Ghersin1, Michelle Toker2, Urmi Khanna2, Rachel Schwartz1, Benedict Wu3 and Anand Kumthekar2, 1Albert Einstein College of Medicine, Bronx, NY, 2Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, 3Montefiore Medical Center, Bronx, NY

Meeting: ACR Convergence 2023

Keywords: Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0691–0721) Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: IgA vasculitis (IgAV) is associated with malignancy in adult patients [1,2]. The clinical characteristics, temporal relationship, and underlying mechanisms of malignancy-associated IgAV are not well understood. Currently, there are no evidence-based screening guidelines for occult malignancies in adults presenting with IgAV.

Methods: We performed a systematic literature review of five major databases: Cochrane Library, Embase.com, PubMed.gov, Google Scholar, and Web of Science Core Collection using the Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) guidelines. A combination of multiple synonyms, controlled vocabulary search terms (MeSH in PubMed and Emtree in Embase), and exhaustive text words were used to search the databases. Two independent reviewers selected studies, extracted data, and determined study quality. A third reviewer adjudicated the article if there was a discrepancy between the 2 reviewers. The articles met inclusion criteria if they contained information regarding IgAV and malignancy in adults older than 18 years-old. Non-English articles and articles older than 30 years-old were excluded.

Results: We screened 967 studies and 93 articles were included, comprising of 108 individual patient cases (Figure 1). The mean age of patients was 60.3±12.9 years, and the majority (n=71, 65.7%) were male (Table 1). Solid malignancy was more commonly associated with IgAV than hematologic malignancy (67.7% vs 32.4%). Malignancy preceded IgAV for most patients with solid cancer, whereas for most with hematological cancer, IgAV preceded malignancy or was diagnosed synchronously. Patients with IgAV and solid malignancies had a significantly higher mortality rate compared to patients with IgAV and hematological malignancies (38.6% vs. 16.7%, p≤0.05). Patients with solid malignancies were also more likely to exhibit systemic involvement of IgAV, including renal, gastrointestinal, joint, and cutaneous symptoms, although the differences were not significant. The majority of patients with skin biopsy had IgA on DIF (71.2%), and of the patients that reported serum IgA levels, 26 (68.2%) had elevated serum IgA.

Conclusion: To our knowledge, this is the largest systematic review of IgAV associated with malignancy. Based on our findings, screening older patients with new-onset or recurring IgAV for malignancy, particularly solid organ cancer, should be considered. Serum IgA levels might serve as a useful, non-invasive screening test since elevated IgA may correlate with underlying malignancy, though further studies are needed to validate these findings.

References
1. Mitsui H, Shibagaki N, Kawamura T, Matsue H, Shimada S. A clinical study of Henoch‐Schönlein Purpura associated with malignancy. Journal of the European Academy of Dermatology and Venereology 2009;23:394-401.

2. Hankard A, Michot J-M, Terrier B, et al. New insights on IgA vasculitis with underlying solid tumor: a nationwide French study of 30 patients. Clinical Rheumatology 2021;40:1933-40.

Supporting image 1

Flowchart illustrating article selection and inclusion process.

Supporting image 2

Summary of sample demographic information, including age, sex, and race/ethnicity, and clinical information, including relative timing, systemic involvement, pathology, serology , and outcomes, by malignancy type.


Disclosures: H. Ghersin: None; M. Toker: None; U. Khanna: None; R. Schwartz: None; B. Wu: None; A. Kumthekar: None.

To cite this abstract in AMA style:

Ghersin H, Toker M, Khanna U, Schwartz R, Wu B, Kumthekar A. The Association of IgA Vasculitis and Malignancy in Adults: A Systematic Review [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/the-association-of-iga-vasculitis-and-malignancy-in-adults-a-systematic-review/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-association-of-iga-vasculitis-and-malignancy-in-adults-a-systematic-review/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology